CompletedPhase 1NCT06665724

Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Universität Münster
Principal Investigator
Walter Stummer, Univ.-Prof. Dr. med.
Department of Neurosurgery, University Hospital Münster, Münster, Germany, 48149
Intervention
5-Aminolevulinic acid Hydrochloride (Gliolan®)(drug)
Enrollment
16 enrolled
Eligibility
18 years · All sexes
Timeline
20252026

Study locations (1)

Collaborators

Alpheus Medical, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06665724 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials